Comparison of the efficacy and safety of zotarolimus [Endeavor]-eluting stent versus sirolimus [Cypher]-eluting stent versus paclitaxel [Taxus]-eluting stent for acute myocardial infarction patients

Trial Profile

Comparison of the efficacy and safety of zotarolimus [Endeavor]-eluting stent versus sirolimus [Cypher]-eluting stent versus paclitaxel [Taxus]-eluting stent for acute myocardial infarction patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Adverse reactions
  • Acronyms ZEST-AMI
  • Most Recent Events

    • 23 Feb 2011 Planned number of patients changed from 1500 to NULL.
    • 15 Nov 2009 Results have been published (American Journal of Cardiology 104: 1370-1376, No. 10, 15 Nov 2009.)
    • 31 Oct 2008 Results have been reported in a Cordis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top